logo

For the Inventor, By the Inventor

Riehen, Switzerland

Albrecht Edenhofer

This inventor holds 16 USPTO granted patents, plus 2 CIPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Hoffmann-La Roche Inc.. Active years: 1976-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Albrecht Edenhofer. Retrieved from https://idiyas.com/inventor/albrecht-edenhofer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.6

ph-index = 8

Forward Citations = 212(Granted Patents)


Location History:

  • Basel, CH (1976)
  • Riehen, CH (1976 - 2002)

Company Filing History:

goldMedal16 out of 5,027 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 1976-2002

Loading Chart...
Loading Chart...
Areas of Expertise:
Thiazole Derivatives
Antithrombic Peptides
Carboxamides
Sulfonamides
Acetic Acid Derivatives
Renin Inhibitors
Pyridine Compounds
Phenylacetic Acid Derivatives
Cyanoethyl Acetamidine
Tetrahydropyridine Derivatives
Phenyl-Pyrimidinium Salts
N-Terminal Amidino Moieties
16 patents (USPTO):Explore Patents
1. 6344562 - Thiazole derivatives (2002-02-05),
2. 6320054 - Thiazole derivatives (2001-11-20),
3. 6100282 - Thiazole derivatives (2000-08-08),
4. 6001855 - Thiazole derivatives (1999-12-14),
5. 5663297 - Antithrombic peptides (1997-09-02),
6. 5430024 - Peptides bearing N-terminal amidino moieties and their use as inhibitors (1995-07-04),
7. 5399585 - Carboxamides and sulfonamides compounds which have useful pharmaceutical (1995-03-21),
8. 5273982 - Acetic acid derivatives (1993-12-28),
9. 5256812 - Carboxamides and sulfonamides (1993-10-26),
10. 5250517 - Renin inhibiting compounds (1993-10-05),
11. 5084466 - Novel carboxamide pyridine compounds which have useful pharmaceutical (1992-01-28),
12. 5039805 - Novel benzoic and phenylacetic acid derivatives (1991-08-13),
13. 4692450 - Phenyl-pyrimidinium, thiazolium or imidazolium salts and use in (1987-09-08),
14. 4675328 - Phenyl-pyridinium salts and use thereof in inhibiting intestinal (1987-06-23),
15. 3985785 - Cyanoethyl acetamidine compounds (1976-10-12),

Title: Inventor Spotlight: Albrecht Edenhofer

Introduction

Albrecht Edenhofer, based in Riehen, Switzerland, is a prominent inventor known for his contributions in the field of chemical compounds. With an impressive portfolio, he holds a total of 16 patents, showcasing his innovative spirit and dedication to advancing scientific knowledge.

Latest Patents

Among his latest contributions to the field, Albrecht has developed a series of thiazole derivatives, compounds that could have substantial implications in various applications. His work continues to push the boundaries of chemical research, focusing on the unique properties and potential uses of these compounds.

Career Highlights

Albrecht is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His tenure at the company has allowed him to collaborate with some of the industry's best minds while focusing on groundbreaking research and development.

Collaborations

Throughout his career, Albrecht has worked alongside notable colleagues, including Leo Alig and Thomas Weller. These collaborations have fostered a creative environment that encourages innovation and leads to the development of pioneering technologies and compounds.

Conclusion

Albrecht Edenhofer's work exemplifies the role of inventors in shaping the future through innovation. His expertise and commitment to research in thiazole derivatives not only highlight his accomplishments but also pave the way for further advancements in the field. As he continues to contribute to the scientific community, his patents remain a testament to his ingenuity and collaborative spirit.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…